Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15694025 | 0.92 | BCHE (0.33) | HTR1AABCB1BLMKDM4EMEN1 | |
| SCHEMBL8008476 | 0.79 | CETP (0.31) | — | |
| SCHEMBL12551199 | 0.77 | KMT2A (0.33) | HTR1ACASP1CASP7KMT2A | |
| SCHEMBL15693085 | 0.73 | KMT2A (0.32) | HTR1AKMT2AALDH1A1 | |
| SCHEMBL12551202 | 0.71 | KMT2A (0.32) | KMT2A | |
| SCHEMBL15694049 | 0.71 | ATM (0.32) | — | |
| SCHEMBL15693076 | 0.62 | — | — | |
| SCHEMBL9870623 | 0.62 | AR (0.33) | — | |
| SCHEMBL9745242 | 0.62 | RAB9A (0.44) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12551209 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722714-B2 | Oxazolidine derivatives as NMDA antagonists | The Honk Kong University of Science and Technology (CN) | 2014-05-13 | — | — | US | disclosed |
| US-20110144168-A1 | OXAZOLIDINE DERIVATIVES AS NMDA ANTAGONISTS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2011-06-16 | — | — | US | disclosed |
| WO-2009092324-A1 | OXAZOLIDINE DERIVATIVES AS NMDA ANTAGONISTS | HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144168-A1 | OXAZOLIDINE DERIVATIVES AS NMDA ANTAGONISTS | GRIN1, GRIN2A, GRIN3A | HTR1A 728/4885ABCB1 3509/4885BLM 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.